BNP Paribas Financial Markets Has $86,000 Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

BNP Paribas Financial Markets grew its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 97.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,074 shares of the biotechnology company’s stock after purchasing an additional 7,421 shares during the period. BNP Paribas Financial Markets’ holdings in Anavex Life Sciences were worth $86,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AVXL. SG Americas Securities LLC acquired a new stake in Anavex Life Sciences during the 2nd quarter worth $57,000. Bank of New York Mellon Corp increased its holdings in shares of Anavex Life Sciences by 17.1% in the second quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock worth $1,184,000 after acquiring an additional 40,895 shares in the last quarter. Rhumbline Advisers raised its position in shares of Anavex Life Sciences by 15.8% during the second quarter. Rhumbline Advisers now owns 119,289 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 16,293 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Anavex Life Sciences by 483.8% during the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after purchasing an additional 386,537 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Anavex Life Sciences in the 2nd quarter valued at approximately $166,000. 31.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

AVXL has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Anavex Life Sciences in a report on Wednesday, November 27th. D. Boral Capital reissued a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Monday, November 25th.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock opened at $8.69 on Thursday. The firm has a market cap of $736.88 million, a price-to-earnings ratio of -17.38 and a beta of 0.73. The stock’s 50-day moving average is $7.55 and its 200-day moving average is $6.11. Anavex Life Sciences Corp. has a one year low of $3.25 and a one year high of $10.45.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.